Corporate GovernanceApr 28, 2026, 05:17 PM
BLFS Amends 2025 10-K for Governance, Executive Comp; 2025 Revenue +29%
AI Summary
BioLife Solutions, Inc. filed an Amendment No. 1 to its 2025 Annual Report on Form 10-K/A to update Part III, including corporate governance, executive compensation, and director information, as it does not intend to file a definitive proxy statement within 120 days. The amendment also noted the retirement of Karen Foster and the elimination of Sarah Aebersold's position. The company highlighted strong 2025 performance with revenue up 29% to $96.2 million and adjusted EBITDA of $25.0 million, alongside strategic acquisitions and divestments.
Key Highlights
- BLFS filed 10-K/A to amend 2025 Annual Report Part III (Items 10-14).
- Amendment due to not filing definitive proxy statement within 120 days.
- Karen Foster retired as Chief Quality and Operations Officer effective March 31, 2026.
- Sarah Aebersold's Chief HR Officer position eliminated March 20, 2026.
- 2025 Revenue increased to $96.2 million, up 29% year-over-year.
- 2025 Adjusted EBITDA was $25.0 million, representing 26% of revenue.
- Acquired PanTHERA CryoSolutions in April 2025 for $11.5 million cash, $4.5 million stock.
- Divested SAVSU Technologies in October 2025 for $23.3 million cash.
- Several directors and officers had delinquent Section 16(a) reports in 2025.